AviadoBio at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
AviadoBio brings 4 presentations to ESGCT 2026 in Hamburg. Its programme centres on AAV-delivered microRNA that silences disease genes in the brain, including MAPT knockdown in human neurons and after intravenous dosing. It also tests synthetic promoters designed for expression in neurons and glial cells.
| Organization | ESGCT 2026 Attendance |
|---|---|
AviadoBio London, UK | |
Develops AAV gene therapies for neurodegenerative diseases such as frontotemporal dementia, including AAV-delivered microRNA to silence MAPT. | Poster Wed Oct 28 1:30pm–3:30pm Leveraging the vMiXTM miRNA platform to silence alpha-synuclein (SNCA) as a therapeutic strategy for synucleinopathies Poster Thu Oct 29 2:00pm–4:00pm Evaluation of rationally designed synthetic promoters for expression in neurons and glial cells Poster Thu Oct 29 2:00pm–4:00pm Silencing of MAPT via AVB-406 in human iPSC-derived neurons: A translational framework for neurodegenerative disease. Talk Thu Oct 29 5:15pm–6:00pm AVB-406: An intravenous AAV-miRNA achieving sustained MAPT knockdown for the treatment of Alzheimer's disease and other tauopathies Vectors and delivery (AAV, lentiviral, LNP)RNA and oligonucleotide therapies |
Instantly find 20 buyers from AviadoBio
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction